98 related articles for article (PubMed ID: 16397277)
21. Fodipir and its dephosphorylated derivative dipyridoxyl ethyldiamine are involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death.
Laskar A; Andersson RG; Li W
Pharmacology; 2013; 92(3-4):182-6. PubMed ID: 24080534
[TBL] [Abstract][Full Text] [Related]
22. Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction.
Skjold A; Amundsen BH; Wiseth R; Støylen A; Haraldseth O; Larsson HB; Jynge P
J Magn Reson Imaging; 2007 Sep; 26(3):720-7. PubMed ID: 17729351
[TBL] [Abstract][Full Text] [Related]
23. Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR.
Schmidt PP; Toft KG; Skotland T; Andersson K
J Biol Inorg Chem; 2002 Mar; 7(3):241-8. PubMed ID: 11935348
[TBL] [Abstract][Full Text] [Related]
24. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
25. Metalloantibiotic Mn(II)-bacitracin complex mimicking manganese superoxide dismutase.
Piacham T; Isarankura-Na-Ayudhya C; Nantasenamat C; Yainoy S; Ye L; Bülow L; Prachayasittikul V
Biochem Biophys Res Commun; 2006 Mar; 341(4):925-30. PubMed ID: 16455051
[TBL] [Abstract][Full Text] [Related]
26. [Cancer, reactive oxygen species and chemotherapy-induced peripheral neuropathy].
Batteux F; Cerles O; Nicco C
Med Sci (Paris); 2014 Dec; 30(12):1078-80. PubMed ID: 25537035
[No Abstract] [Full Text] [Related]
27. Hepatobiliary contrast material: a magic bullet for sensitivity and specificity?
Mitchell DG
Radiology; 1993 Jul; 188(1):21-2. PubMed ID: 8511300
[No Abstract] [Full Text] [Related]
28. Exploring multifunctional features of necrosis avid contrast agents.
Ni Y; Cresens E; Adriaens P; Dymarkowski S; Bogaert J; Zhang H; Bosmans H; Verbruggen A; Marchal G
Acad Radiol; 2002 Aug; 9 Suppl 2():S488-90. PubMed ID: 12188317
[No Abstract] [Full Text] [Related]
29. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics.
Kim JH; Kim MJ; Park YN; Lee JT; Kim BR; Chung JB; Choi JS; Kim KS; Kim KW
Clin Radiol; 2008 Nov; 63(11):1195-204. PubMed ID: 18929037
[TBL] [Abstract][Full Text] [Related]
30. Determination of mangafodipir trisodium and related impurities in bulk substance and pharmaceutical formulation by ion-pair high-performance liquid chromatography.
Gjerde H; Snøtun A; Hem H; Larsen KH; Døhl J
J Pharm Biomed Anal; 2001 Apr; 25(1):109-14. PubMed ID: 11274864
[TBL] [Abstract][Full Text] [Related]
31. Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
Karlsson JOG
EBioMedicine; 2019 Sep; 47():27. PubMed ID: 31466917
[No Abstract] [Full Text] [Related]
32. Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report.
Yri OE; Vig J; Hegstad E; Hovde O; Pignon I; Jynge P
Acta Oncol; 2009; 48(4):633-5. PubMed ID: 19169914
[No Abstract] [Full Text] [Related]
33. Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir? - Authors' reply.
Dear JW
EBioMedicine; 2019 Sep; 47():28. PubMed ID: 31492564
[No Abstract] [Full Text] [Related]
34. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Rockall AG; Planche K; Power N; Nowosinska E; Monson JP; Grossman AB; Reznek RH
Neuroendocrinology; 2009; 89(3):288-95. PubMed ID: 19023191
[TBL] [Abstract][Full Text] [Related]
35. Contrast-enhanced MR imaging in the diagnosis and preservation of cardiac viability.
Smith HJ
Acta Radiol; 2001 Nov; 42(6):539. PubMed ID: 11736697
[No Abstract] [Full Text] [Related]
36. Breaking away from the norm: a new perspective on cancer therapeutics.
Näsström J
Drug Discov Today; 2014 Oct; 19(10):1508-9. PubMed ID: 25111869
[No Abstract] [Full Text] [Related]
37. The need for effective contrast agents to enhance the performance of MR imaging.
Grant D; Refsum H; Rummeny E; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):623-5. PubMed ID: 9245954
[No Abstract] [Full Text] [Related]
38. Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy.
Grant D; Zech K; Holtz E
Invest Radiol; 1994 Jun; 29 Suppl 2():S249-50. PubMed ID: 7928247
[No Abstract] [Full Text] [Related]
39. Enhancement of pancreas and diagnosis of pancreatitis using manganese dipyridoxyl diphosphate.
Baba Y; Lerch MM; Tanimoto A; Kreft BP; Saluja AK; Zhao L; Chen J; Steer ML; Stark DD
Invest Radiol; 1994 Jun; 29 Suppl 2():S300-1. PubMed ID: 7928263
[No Abstract] [Full Text] [Related]
40. Tumor models and specific contrast agents for small animal imaging in oncology.
Ni Y; Wang H; Chen F; Li J; DeKeyzer F; Feng Y; Yu J; Bosmans H; Marchal G
Methods; 2009 Jun; 48(2):125-38. PubMed ID: 19328231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
